You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Article info

Article menu

Download PDFPDF

XML
Research Article
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Authors

  • Daan P. Hurkmans Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands Department of PulmonologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Edwin A. Basak Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Tanja van Dijk Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Darlene Mercieca Department of PulmonologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Marco W. J. Schreurs Department of ImmunologyErasmus University Medical Center Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Annemarie J. M. Wijkhuijs Department of ImmunologyErasmus University Medical Center Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Sander Bins Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Esther Oomen-de Hoop Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Reno Debets Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Markus Joerger Department of Medical Oncology and HematologyCantonal Hospital St. Gallen Switzerland PubMed articlesGoogle scholar articles
  • Arlette Odink Department of Radiology & Nuclear MedicineErasmus University Medical Center Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Astrid A. M. van der Veldt Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands Department of Radiology & Nuclear MedicineErasmus University Medical Center Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Cor H. van der Leest Department of PulmonologyAmphia Hospital Breda The Netherlands PubMed articlesGoogle scholar articles
  • Joachim G. J. V. Aerts Department of PulmonologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Ron H. J. Mathijssen Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands PubMed articlesGoogle scholar articles
  • Stijn L. W. Koolen Department of Medical OncologyErasmus MC Cancer Institute, Erasmus University Medical Center PO Box 2040 3000 CA Rotterdam The Netherlands Department of Hospital PharmacyErasmus University Medical Center Rotterdam The Netherlands PubMed articlesGoogle scholar articles

Citation

Hurkmans DP, Basak EA, van Dijk T, et al
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Journal for ImmunoTherapy of Cancer 2019;7:192. doi: 10.1186/s40425-019-0669-y
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.